103 related articles for article (PubMed ID: 11411555)
1. Stealth polycyanoacrylate nanoparticles as tumor necrosis factor-alpha carriers: pharmacokinetics and anti-tumor effects.
Li YP; Pei YY; Zhou ZH; Zhang XY; Gu ZH; Ding J; Zhou JJ; Gao XJ; Zhu JH
Biol Pharm Bull; 2001 Jun; 24(6):662-5. PubMed ID: 11411555
[TBL] [Abstract][Full Text] [Related]
2. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size.
Fang C; Shi B; Pei YY; Hong MH; Wu J; Chen HZ
Eur J Pharm Sci; 2006 Jan; 27(1):27-36. PubMed ID: 16150582
[TBL] [Abstract][Full Text] [Related]
3. Effect of MePEG molecular weight and particle size on in vitro release of tumor necrosis factor-alpha-loaded nanoparticles.
Fang C; Shi B; Pei YY
Acta Pharmacol Sin; 2005 Feb; 26(2):242-9. PubMed ID: 15663906
[TBL] [Abstract][Full Text] [Related]
4. [Influence of particle size and MePEG molecular weight on in vitro macrophage uptake and in vivo long circulating of stealth nanoparticles in rats].
Fang C; Shi B; Hong MH; Pei YY; Chen HZ
Yao Xue Xue Bao; 2006 Apr; 41(4):305-12. PubMed ID: 16856473
[TBL] [Abstract][Full Text] [Related]
5. [Preparation and stability of recombinant human tumor necrosis factor-alpha-loaded stealth nanoparticles].
Fang C; Shi B; Pei YY
Yao Xue Xue Bao; 2004 Nov; 39(11):939-43. PubMed ID: 15696938
[TBL] [Abstract][Full Text] [Related]
6. PEGylated polycyanoacrylate nanoparticles as tumor necrosis factor-alpha carriers.
Li YP; Pei YY; Zhou ZH; Zhang XY; Gu ZH; Ding J; Zhou JJ; Gao XJ
J Control Release; 2001 Apr; 71(3):287-96. PubMed ID: 11295221
[TBL] [Abstract][Full Text] [Related]
7. Body distribution and in situ evading of phagocytic uptake by macrophages of long-circulating poly (ethylene glycol) cyanoacrylate-co-n-hexadecyl cyanoacrylate nanoparticles.
Huang M; Wu W; Qian J; Wan DJ; Wei XL; Zhu JH
Acta Pharmacol Sin; 2005 Dec; 26(12):1512-8. PubMed ID: 16297352
[TBL] [Abstract][Full Text] [Related]
8. PEGylated recombinant human tumor necrosis factor alpha: pharmacokinetics and anti-tumor effects.
Li YP; Pei YY; Zhou ZH; Zhang XY; Gu ZH; Ding J; Gao XJ; Zhu JH
Biol Pharm Bull; 2001 Jun; 24(6):666-70. PubMed ID: 11411556
[TBL] [Abstract][Full Text] [Related]
9. Stealth PEG-PHDCA niosomes: effects of chain length of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity.
Shi B; Fang C; Pei Y
J Pharm Sci; 2006 Sep; 95(9):1873-87. PubMed ID: 16795003
[TBL] [Abstract][Full Text] [Related]
10. PEGylated polycyanoacrylate nanoparticles as salvicine carriers: synthesis, preparation, and in vitro characterization.
Li YP; Zhou ZH; Pei YY; Zhang XY; Gu ZH; Yuan WF
Acta Pharmacol Sin; 2001 Jul; 22(7):645-50. PubMed ID: 11749831
[TBL] [Abstract][Full Text] [Related]
11. PEGylated recombinant human tumor necrosis factor alpha: preparation and anti-tumor potency.
Li YP; Pei YY; Ding J; Shen ZM; Zhang XY; Gu ZH; Zhou JJ
Acta Pharmacol Sin; 2001 Jun; 22(6):549-55. PubMed ID: 11747763
[TBL] [Abstract][Full Text] [Related]
12. Stealth PEG-PHDCA niosomes: effects of chain length of PEG on niosomes in vitro complement consumption and phagocytic uptake.
Shi B; Fang C; You MX; Hong MH; Pei YY
Yao Xue Xue Bao; 2005 Nov; 40(11):976-81. PubMed ID: 16499079
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory and toxic effects of free and liposome-encapsulated tumor necrosis factor alpha in rats.
Debs RJ; Fuchs HJ; Philip R; Brunette EN; Düzgüneş N; Shellito JE; Liggitt D; Patton JR
Cancer Res; 1990 Jan; 50(2):375-80. PubMed ID: 2295077
[TBL] [Abstract][Full Text] [Related]
14. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting.
Peracchia MT; Fattal E; Desmaële D; Besnard M; Noël JP; Gomis JM; Appel M; d'Angelo J; Couvreur P
J Control Release; 1999 Jun; 60(1):121-8. PubMed ID: 10370176
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of recombinant human tumor necrosis factor-alpha in rats. Effects of size and number of doses and nephrectomy.
Ferraiolo BL; McCabe J; Hollenbach S; Hultgren B; Pitti R; Wilking H
Drug Metab Dispos; 1989; 17(4):369-72. PubMed ID: 2571474
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and antitumor effects of the drug containing TNF-α in nanoparticles.
Gamaley SG; Bateneva AV; Sysoeva GM; Danilenko ED; Lebedev LR; Masycheva VI
Bull Exp Biol Med; 2010 Sep; 149(3):320-3. PubMed ID: 21246092
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and tissue distribution of recombinant human tumor necrosis factor-alpha in mice.
Ferraiolo BL; Moore JA; Crase D; Gribling P; Wilking H; Baughman RA
Drug Metab Dispos; 1988; 16(2):270-5. PubMed ID: 2898346
[TBL] [Abstract][Full Text] [Related]
18. Release profiles of recombinant human tumor necrosis factor from Ca(2+)-triggering liposome in vivo.
Yasui K; Fujioka H; Nakamura Y
Biol Pharm Bull; 1996 Feb; 19(2):246-51. PubMed ID: 8850316
[TBL] [Abstract][Full Text] [Related]
19. Analysis of plasma protein adsorption onto PEGylated nanoparticles by complementary methods: 2-DE, CE and Protein Lab-on-chip system.
Kim HR; Andrieux K; Delomenie C; Chacun H; Appel M; Desmaële D; Taran F; Georgin D; Couvreur P; Taverna M
Electrophoresis; 2007 Jul; 28(13):2252-61. PubMed ID: 17557357
[TBL] [Abstract][Full Text] [Related]
20. Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3.
Cimoli G; Valenti M; Parodi S; Mazzoni A; De Sessa F; Conte P; Russo P
Oncol Res; 1993; 5(8):311-23. PubMed ID: 8012063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
